## Abstract Recent studies have revealed that Foxp3^+^CD25^+^CD4^+^ regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological selfβtolerance, play critical roles for the control of antitumor immune responses. For example, a large number of Foxp3^+^Tregs infil
Prognostic significance of regulatory T cells in tumor
β Scribed by Cailin Moira Wilke; Ke Wu; Ende Zhao; Guobin Wang; Weiping Zou
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- French
- Weight
- 183 KB
- Volume
- 127
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Since entering the immunological stage several decades ago, regulatory T cell biology has been realized as fundamentally important in the prevention of autoimmune conditions, induction of transplant tolerance and the immune response to cancer. The role of regulatory T cells in tumor immunobiology is still being elucidated. Currently, regulatory T cells are implicated in the dampening of antitumor Tβcell responses both through direct and indirect means. A number of investigators have demonstrated that regulatory T cell density and location may serve as independent prognostic factors in several types of cancer and are alternately detrimental or beneficial to patient survival. In this article, we will review the characteristics and functional phenotype of classical regulatory T cells, describe their distribution and quantification in tumorβbearing hosts and summarize recent studies investigating the prognostic significance of regulatory T cell number and locality in various cancers.
π SIMILAR VOLUMES
Mammary angiosarcoma appears to be a heterogeneous group of neoplasms morphologically, in which growth pattern or grade is an important prognostic factor. In this report, 63 patients whose slides were seen in consultation and/or who were treated at Memorial Sloan-Kettering Cancer Center (MSKCC) are
## BACKGROUND. In vitro studies have shown an antiproliferative effect of tumor necrosis factor (TNF) against various nonsmall cell lung carcinoma (NSCLC) cell lines. However, clinical trials of combined interleukin-2 and TNF-β£ in patients with advanced NSCLC have demonstrated both conflicting and